Skip to main content

Advertisement

SpringerLink
Log in

Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year Etanercept exposure

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this retrospective study was to record the achievement of clinical remission (CR) in juvenile idiopathic arthritis patients under a 2–10 years’ administration of Etanercept (ETN) and to detect any variables associated with CR. Patients previously resistant to conventional regimens were enrolled. The annual impact of ETN was assessed by: (a) the American College of Rheumatology pediatric criteria (ACRpedi), (b) the pre- and posttreatment disease activity score (juvenile arthritis disease activity score [JADAS71]), and (c) Wallace’s criteria for CR. A total of 41 patients (F: 31) were registered. The median age and disease duration at baseline were 10.6 and 4.17 years, respectively, and their disease course was mainly polyarthritis (32/41). In respect to baseline, there was an impressive JADAS71 reduction posttreatment, most prominent after the first year. From year 1 to 5, more than 50 % of the patients achieved and retained CR and 66 % reached an ACRpedi 70, whereas after the 5th year, no patient was withdrawn due to an ACRpedi <30. JADAS71 at baseline was not associated with the subsequent CR achievement. However, JADAS71 1-year posttreatment had a significant association with the CR of the second posttreatment year, (p = 0.028, OR 0.79; 95 % CI 0.63–0.98) and a similar trend was observed for the following years. These findings emphasize the sustained impact of ETN in the achievement of CR. A low JADAS71 score 1-year posttreatment, may be associated with the maintenance of CR over the next treatment year.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gowdie PJ, Tse SM (2012) Juvenile idiopathic arthritis. Pediatr Clin North Am 59:301–327

    Article  PubMed  Google Scholar 

  2. Gullick NJ, Scott DL (2012) Drug therapy of inflammatory arthritis. Clin Med 12:357–363

    Article  PubMed  Google Scholar 

  3. Baildam E (2012) A commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis. BMC Med 10:59

    Article  PubMed  Google Scholar 

  4. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63:465–482

    Article  Google Scholar 

  5. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JUMBO. Rheumatology (Oxford) 51:1407–1415

    Article  CAS  Google Scholar 

  6. Papsdorf V, Horneff G (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 50:214–221

    Article  CAS  PubMed  Google Scholar 

  7. Russo RAG, Katsikas MM (2009) Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 36:1078–1082

    Article  CAS  PubMed  Google Scholar 

  8. Ringold S, Wallace CA (2007) Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol 19:471–476

    Article  PubMed  Google Scholar 

  9. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392

    PubMed  Google Scholar 

  10. Greek Rheumatology Society. [Greek Rheumatology Society’s recommendations for the treatment of rheumatic diseases with biologic agents]. [Article in Greek] www.ere.gr/-Pdf/ere-systaseis.pdf. accessed Feb 2005

  11. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G et al (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61:658–666

    Article  PubMed  Google Scholar 

  12. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile idiopathic arthritis. Arthritis Rheum 40:1202–1209

    CAS  PubMed  Google Scholar 

  13. Pratsidou-Gertsi P, Vougiouka O, Tsitsami E, Ruperto N, Siamopoulou-Mavridou A, Dracou C et al (2001) The Greek version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19(suppl 23):S76–S80

    CAS  PubMed  Google Scholar 

  14. Poznanski AK, Hernandez RJ, Guire KE, Bereza U, Garn SN (1978) Carpal length in children—a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. Radiology 129:661–668

    CAS  PubMed  Google Scholar 

  15. van Rossum MA, Boers M, Zwinderman AH, van Soesbergen RM, Wieringa H, Fiselier TJ et al (2005) Arthritis Rheum 52:2865–2872

    Article  PubMed  Google Scholar 

  16. Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or Etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247

    Article  CAS  PubMed  Google Scholar 

  17. Lovell DJ, Reiff A, Olcay Y, Schneider R, Nocton J, Stein LD et al (2006) Long-term safety and efficacy of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum 54:1987–1994

    Article  PubMed  Google Scholar 

  18. Zhou H (2005) Clinical pharmacokinetics of Etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490–497

    Article  CAS  PubMed  Google Scholar 

  19. Pratsidou-Gertsi P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F (2010) A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28:919–922

    CAS  PubMed  Google Scholar 

  20. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C et al (2012) Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis defining criteria based on the juvenile arthritis disease activity score. Arthr Rheum 64:2366–2374

    Article  Google Scholar 

  21. Filocamo G, Consolaro A, Solari N, Palmisani E, Dalprΰ S, Suffia C et al (2012) Recent advances in quantitative assessment of juvenile idiopathic arthritis. Ann Paediatr Rheumatol 1:84–96

    Article  Google Scholar 

  22. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E (2003) Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year follow up. J Rheumatol 30:579–584

    PubMed  Google Scholar 

  23. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O’Neil KM, Zeft AS et al (2012) Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 64:2012–2021

    Article  PubMed  Google Scholar 

  24. Otten MH, Prince FHM, Armbrust W, ten Cate R, Hoppenreijs EPAH, Twilt M et al (2011) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306:2340–2347

    Article  CAS  PubMed  Google Scholar 

  25. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C et al (2012) Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 64:2366–2374

    Article  PubMed  Google Scholar 

  26. Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71:700–706

    Article  CAS  PubMed  Google Scholar 

  27. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Reed M et al (2003) Early predictors of long term outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 30:585–593

    PubMed  Google Scholar 

  28. Solari N, Palmisani E, Consolaro A, Pistorio A, Lanni S, Dalprà S et al (2013) Predictors of achievement of inactive disease in children with juvenile idiopathic arthritis treated with Etanercept. J Rheumatol 40:192–200

    Article  CAS  PubMed  Google Scholar 

  29. Nielsen S, Ruperto N, Gerloni V, Simonini E, Cortis E, Lepore L et al (2008) Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 26:688–692

    CAS  PubMed  Google Scholar 

  30. Smolen JS, Aletaha D, Steiner G (2009) Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 68:159–162

    Article  CAS  PubMed  Google Scholar 

  31. Ruth NM, Passo MH (2012) Juvenile idiopathic arthritis: management and therapeutic options. Ther Adv Musculoskelet Dis 4:99–110

    Article  CAS  PubMed  Google Scholar 

  32. Ellis JA, Munro JE, Ponsonby AL (2010) Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford) 49:411–425

    Article  Google Scholar 

  33. Berkun Y, Padeh S (2010) Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 9:A319–A324

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

This work was supported by an investigator initiative research grant from Pfizer Inc.

Author information

Authors and Affiliations

  1. Pediatric Immunology and Rheumatology Referral Center, 1st Department of Pediatrics, Aristotle University, Ippokration Hospital, Thessaloniki, Greece

    Maria Trachana, Polyxeni Pratsidou-Gertsi & Grigoris Pardalos

  2. Pediatric Radiology Department, Ippokration Hospital, Thessaloniki, Greece

    Maria Badouraki

  3. Department of Hygiene and Epidemiology, Aristotle University, Thessaloniki, Greece

    Anna Bettina Haidich

  4. Kleious Str 6, GR 54633, Thessaloniki, Greece

    Maria Trachana

Authors
  1. Maria Trachana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Polyxeni Pratsidou-Gertsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Badouraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Bettina Haidich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Grigoris Pardalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Trachana.

Additional information

Maria Trachana and Polyxeni Pratsidou-Gertsi contributed equally.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trachana, M., Pratsidou-Gertsi, P., Badouraki, M. et al. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year Etanercept exposure. Clin Rheumatol 32, 1191–1197 (2013). https://doi.org/10.1007/s10067-013-2261-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-013-2261-z

Keywords

Search

Navigation